The OBJECTIVE was to evaluate the clinical viability of the author's pharmacodialysis device for the treatment of subarachnoid hemorrhage (SAH). This neuroengineered system, implantable in the neurocranium, can perform subarachnoid drug delivery, edema drainage, neurotoxin dialysis, and electroencephalography (EEG) recording for years, hence its therapeutic potential in SAH as a Neurocranial Pharmacodialysis Device (NPD). The METHOD of the evaluation consisted of reexamining the related medical inventions, considering the experience with earlier device versions, and interpreting the context of relevant studies by other investigators. The RESULTS showed the following four facts: (1) high-grade SAH requiring decompressive craniectomy readily offers, as the last step of the neurosurgical procedure, the safe closure of the opened cranium with the NPD while leaving the efficacy of the decompressive intervention intact. (2) The neurocranially attached NPD can automatically execute, as long as it is necessary, subarachnoid polypharmacy to prevent post-SAH vasospasm, reduce the risk of rebleeding, and provide neuroprotection in delayed cerebral ischemia (DCI), bypassing the blood-brain barrier (BBB) via connected subarachnoid strips. (3) These effects of drug delivery can be optimized with NPD-controlled long-term cleaning of the CSF and drainage of cellular debris, hydrocephalus, and interstitial edema accompanied by the subarachnoid dialysis of potentially neurotoxic extracellular molecules. (4) Safety and efficacy of these NPD operations are monitored, and possible epileptiform EEG is detected, via the wireless EEG system of the device. The CONCLUSION was that complementing conservative therapies with NPD implantation can reduce the current substantial mortality and morbidity among hospitalized survivors of SAH.